Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 2Classical hematology 2

Conditions

Leukemia, Myeloid, Acute 129Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Hematologic Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 65Leukemia 53Myelodysplastic Syndromes 49Lymphoma 34Leukemia, Myelogenous, Chronic, BCR-ABL Positive 30Lymphoma, Non-Hodgkin 29Multiple Myeloma 21Burkitt Lymphoma 21Leukemia, Myelomonocytic, Chronic 20Recurrence 18Neoplasms 18Lymphoma, Large B-Cell, Diffuse 15Leukemia, B-Cell 14Hodgkin Disease 14Myeloproliferative Disorders 13Lymphoma, Mantle-Cell 12Leukemia, Biphenotypic, Acute 12Lymphoma, Follicular 11Lymphoma, B-Cell 11Waldenstrom Macroglobulinemia 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma, B-Cell, Marginal Zone 10Anemia, Refractory, with Excess of Blasts 10Blast Crisis 8Primary Myelofibrosis 7Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 6Myelodysplastic-Myeloproliferative Diseases 6

Interventions

Azacitidine 2venetoclax 1Vorinostat 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
GATA2 Deficiency × Other hematologic neoplasm × 30 days × Clear all
NCT01905826 2026-06-05

Natural History Study of GATA2 Deficiency and Related Disorders

National Institutes of Health Clinical Center (CC)

Recruiting
600 enrolled
MyeloidOther hematologic neoplasm

GATA2 Deficiency, Herpes Simplex, Leukemia, Myelodysplastic Syndromes

NCT06372717 2026-06-01

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

Apollo Therapeutics Ltd

Phase 1 Recruiting
100 enrolled
Classical hematologyOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

NCT01522976 2026-05-29

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
282 enrolled 11 charts
Classical hematologyMyeloidOther hematologic neoplasm

GATA2 Deficiency, Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡